Stock Fundamentals

Company Information

Company Name
Iovance Biotherapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US4622601007
CIK: 0001425205
CUSIP: 37182R102
Currency: USD
Full Time Employees: 975
Phone: 650 260 7120
Fiscal Year End: December
IPO Date: Oct 15, 2010
Description:

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Address:

825 Industrial Road, San Carlos, CA, United States, 94070

Directors & Officers

Name Title Year Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim CEO, President, General Counsel, Corporate Secretary & Director 1974
Ms. Corleen M. Roche Chief Financial Officer 1966
Dr. Igor P. Bilinsky Ph.D. Chief Operating Officer 1973
Dr. Raj K. Puri M.D., Ph.D. Chief Regulatory Officer 1956
Mr. Daniel G. Kirby Chief Commercial Officer 1972
Ms. Sara Pellegrino Senior Vice President of Investor Relations & Corporate Communications NA
Ms. Tracy Winton Executive Vice President of Human Resources NA
Mr. Howard B. Johnson M.B.A. Chief Business Officer 1960
Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer 1967
Mr. Brian Shew M.B.A. Senior VP & Head of Digital and Information Technology NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
May 23, 2025 Raj K Puri N/A Purchase 5.60K $1.74 $9.74K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 31.08M Mar 31, 2026 6.96% $0.00 5.29%
Mhr Fund Management Llc 28.97M Mar 31, 2026 6.49% $7.43 0.00%
Vanguard Group Inc 27.21M Dec 31, 2025 6.09% $0.00 13.08%
State Street Corp 17.45M Mar 31, 2026 3.91% $0.00 -13.46%
Vanguard Capital Management, LLC 16.62M Mar 31, 2026 3.72% $0.00 0.00%
Two Sigma Investments LLC 13.69M Mar 31, 2026 3.07% $0.04 211.22%
Vanguard Portfolio Management, LLC 11.70M Mar 31, 2026 2.62% $0.00 0.00%
Millennium Management LLC 9.41M Mar 31, 2026 2.11% $0.01 42.95%
The Goldman Sachs Group Inc 8.76M Mar 31, 2026 1.96% $0.00 1.77%
Geode Capital Management, LLC 8.57M Mar 31, 2026 1.92% $0.00 7.27%
Invenomic Capital Management, LP 8.50M Mar 31, 2026 1.90% $1.37 -28.96%
Bank of America Corp 8.49M Mar 31, 2026 1.90% $0.00 -40.54%
D. E. Shaw & Co LP 8.02M Mar 31, 2026 1.80% $0.02 109.32%
Palo Alto Investors, LLC 6.35M Mar 31, 2026 1.42% $3.41 -10.78%
Morgan Stanley - Brokerage Accounts 6.20M Mar 31, 2026 1.39% $0.00 -32.53%
Jane Street Group LLC 4.17M Mar 31, 2026 0.93% $0.00 16.47%
Nuveen, LLC 3.66M Mar 31, 2026 0.82% $0.00 164.38%
HRT FINANCIAL LLC 3.49M Mar 31, 2026 0.78% $0.03 -19.97%
T. Rowe Price Associates, Inc. 3.17M Mar 31, 2026 0.71% $0.00 165.71%
Two Sigma Advisers, LLC 3.02M Dec 31, 2025 0.68% $0.02 184.70%

Shares Statistics

Shares Outstanding: 446.50M
Shares Float: 387.90M
% Insiders: 33.90%
% Institutions: 6,746.80%
Short % Float: 24.99%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 12.48M 2.79% ▲ 0.02% Apr 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 9.01M 2.02% ▼ 0.61% May 31, 2026
3 iShares Russell 2000 ETF 8.05M 1.80% ▲ 0.93% May 29, 2026
4 Invenomic Institutional 5.02M 1.13% ▲ 0.19% Jan 31, 2026
5 Vanguard Small Cap Index 4.51M 1.01% ▼ 0.43% Apr 30, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 3.76M 0.84% ▲ 1.01% Apr 30, 2026
7 Fidelity Small Cap Index 3.31M 0.74% ▲ 9.95% Mar 31, 2026
8 iShares Russell 2000 Value ETF 2.92M 0.66% ▲ 1.35% May 29, 2026
9 Vanguard Small Cap Value Index Inv 2.90M 0.65% ▲ 0.69% Apr 30, 2026
10 iShares Biotechnology ETF 2.59M 0.58% ▲ 1.95% May 29, 2026

Valuation Metrics

Enterprise Value: $1.55B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.82B
EBITDA: $-321.62M
PEG Ratio: $0.00
Book Value: $1.65
Earnings/Share: $-0.92
Profit Margin: -123.90%
Operating Margin: -113.46%
ROA (TTM): -23.65%
ROE (TTM): -47.51%
Revenue (TTM): $285.61M
Revenue/Share (TTM): $0.75
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 44.80%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.20x 0.01x 0.23x N/A -0.01x
2024-12-31 3.74x 0.02x 0.22x N/A -0.04x
2023-12-31 2.79x 0.02x 0.25x N/A -0.02x
2022-12-31 5.24x 0.03x 0.25x -133.63x -0.04x
2021-12-31 5.69x 0.01x 0.20x -759.87x -0.02x
2020-12-31 11.59x 0.01x 0.15x -111.18x -0.02x
2019-12-31 8.10x 0.02x 0.13x N/A -0.04x
2018-12-31 33.02x 0.00x 0.03x N/A 0.00x
2017-12-31 15.09x 0.00x 0.06x N/A 0.00x
2016-12-31 34.12x 0.00x 0.03x N/A 0.00x
2015-12-31 63.79x 0.00x 0.02x -139.30x 0.00x
2014-12-31 27.06x 0.00x 0.04x -2,127.21x 0.00x
2013-12-31 8.74x 0.37x 0.11x -50.91x -0.26x
2012-12-31 0.00x -0.44x 385.85x N/A -0.62x
2011-12-31 0.04x -0.39x 23.48x -140.05x -0.24x
2010-12-31 1.58x 0.00x 0.56x N/A 0.00x
2009-12-31 0.36x 0.00x 2.40x N/A 0.00x
2008-12-31 0.92x 0.00x 0.59x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IOVA.US!